Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 9,584 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care treatment Clear all
Completed Not applicable Interventional Results available

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

NCT03258853
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

SPARK-CGM Implementation

NCT07548372
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Enhanced CGM Interventions, Standard of Care
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional Results available

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

NCT04305457
View directory record Official record
Conditions
Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Shreveport, Louisiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Multilevel Intervention to Increase Colorectal Cancer Screening Tests in Patients With Abnormal Fecal Immunochemical Test Results, PROACT Trial

NCT06822530
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Educational Intervention, Electronic Health Record Review, Interview, Supportive Care, Survey Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 75 Years
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

NCT02089230
View directory record Official record
Conditions
Leukemia
Interventions
MEK 162
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mg, Placebo tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
17,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
234
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

NCT06930495
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Weight loss SOC Treatment with second generation anti-diabetic medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients

NCT01671501
View directory record Official record
Conditions
HIV, Acquired Immunodeficiency Syndrome, Alcoholism, Alcoholic Intoxication, Substance-Related Disorders
Interventions
Motivational Interviewing, Email Feedback, Usual Care
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 14, 2026, 10:34 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fresh RX: NHS 2020

NCT04845230
View directory record Official record
Conditions
Premature Birth, Birth Weight, Post Partum Depression, Health Care Utilization, Nutrition Deficiency Due to Insufficient Food, Housing Problems, Fetal Complications, Food Deprivation
Interventions
FreshRx Nourishing Healthy Starts
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Phase 3 Interventional

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

NCT06401330
View directory record Official record
Conditions
Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions
Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
154
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Active, not recruiting Not applicable Interventional

Serial Brain MRI in Hospitalized Preterm Infants

NCT06052865
View directory record Official record
Conditions
Preterm Birth Complication
Interventions
SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program, SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program, Reference/ Standard of care
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Weeks to 33 Weeks
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional

Using Functional MRI to Evaluate Cognitive Behavioral Therapy Treatment Response in Adults With Chronic Pain

NCT00796536
View directory record Official record
Conditions
Chronic Pain
Interventions
Group cognitive behavioral therapy, Pain education
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT01806675
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Pacifier-Activated Lullaby on Oral Feeding Among Preterm Infants

NCT07819734
View directory record Official record
Conditions
Dysphagia of Newborn
Interventions
Pacifier-Activated Lullaby (PAL) Therapy
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
34 Weeks to 36 Weeks
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Active, not recruiting Phase 3 Interventional

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Chemotherapy, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

OPT-IN: Osteopathic Plagiocephaly Treatment for Infants and Neonates

NCT05848895
View directory record Official record
Conditions
Plagiocephaly, Nonsynostotic, Plagiocephaly, Positional, Plagiocephaly, Cranium; Deformity
Interventions
Osteopathic Manipulative Treatment, Standard of Care Repositioning
Procedure · Behavioral
Lead sponsor
Osteopathy's Promise to Children
Other
Eligibility
1 Day to 4 Months
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00077675
View directory record Official record
Conditions
Infections, Gram-positive Bacterial
Interventions
Telavancin, vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 14, 2026, 10:34 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Combined Laparoscopy With CO2 Intraoperative Colonoscopy Treatment for Colorectal Lesions

NCT00725465
View directory record Official record
Conditions
Colorectal Polyps
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

NCT07225036
View directory record Official record
Conditions
Low-Dose Liver Radiation (LD-LRT), Non Small Cell Lung Cancer, Melanoma, Liver Metastases
Interventions
LD-LRT
Radiation
Lead sponsor
Jordan Kharofa
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Active, not recruiting Phase 2 Interventional

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

NCT04759911
View directory record Official record
Conditions
Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Medullary Carcinoma, Thyroid Gland Papillary Carcinoma, Thyroid Gland Squamous Cell Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01846611
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Trabectedin, DOXIL, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV

NCT04505371
View directory record Official record
Conditions
HIV Infections, Smoking, Smoking Cessation
Interventions
Wellness Intervention for Smokers with HIV
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional

A Pilot Study of mDOT for Immunosuppressant Adherence in Adolescent Kidney Transplant Recipients

NCT03504137
View directory record Official record
Conditions
Medication Adherence, Kidney Transplant
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 14, 2026, 10:34 AM EDT